Publications

Detailed Information

Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci

DC Field Value Language
dc.contributor.authorKim, SH-
dc.contributor.authorPark, WB-
dc.contributor.authorLee, KD-
dc.contributor.authorKang, CI-
dc.contributor.authorKim, HB-
dc.contributor.authorOh, MD-
dc.contributor.authorKim, EC-
dc.contributor.authorChoe, KW-
dc.date.accessioned2024-04-26T01:14:49Z-
dc.date.available2024-04-26T01:14:49Z-
dc.date.created2023-05-01-
dc.date.created2023-05-01-
dc.date.issued2003-09-
dc.identifier.citationClinical Infectious Diseases, Vol.37 No.6, pp.794-799-
dc.identifier.issn1058-4838-
dc.identifier.urihttps://hdl.handle.net/10371/199795-
dc.description.abstractTo determine the outcome of Staphylococcus aureus bacteremia (SAB) on mortality, including the impact of methicillin resistance and an initial delay ( less than or equal to 48 h) of appropriate antibiotics, a retrospective cohort study including 238 patients with SAB was performed. By logistic regression, noneradicable or noneradicated foci, underlying cirrhosis, and cancer were found to be independent predictors of mortality. In patients with eradicable foci, there were no significant differences in the associated mortality rate between methicillin-resistant SAB (11%) and methicillin-susceptible SAB (13%), and between inappropriate ( 13%) and appropriate (10%) empirical therapy, respectively (P = .79 and P = .78, respectively). By logistic regression, it was found that, in the subgroup of patients with noneradicable foci, underlying cirrhosis (odds ratio [OR], 3.1) and methicillin-resistant SAB ( OR, 2.4) were independently associated with mortality.-
dc.language영어-
dc.publisherUniversity of Chicago Press-
dc.titleOutcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci-
dc.typeArticle-
dc.identifier.doi10.1086/377540-
dc.citation.journaltitleClinical Infectious Diseases-
dc.identifier.wosid000185131100008-
dc.identifier.scopusid2-s2.0-0141676166-
dc.citation.endpage799-
dc.citation.number6-
dc.citation.startpage794-
dc.citation.volume37-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorPark, WB-
dc.contributor.affiliatedAuthorKim, HB-
dc.contributor.affiliatedAuthorOh, MD-
dc.contributor.affiliatedAuthorKim, EC-
dc.contributor.affiliatedAuthorChoe, KW-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusMETHICILLIN RESISTANCE-
dc.subject.keywordPlusRISK-
dc.subject.keywordPlusENDOCARDITIS-
dc.subject.keywordPlusINFECTION-
dc.subject.keywordPlusMORTALITY-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusIMPACT-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Immunology, Infectious Diseases, Vaccination, 감염병, 바이러스질환, 예방접종

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share